temozolomide has been researched along with sb 202190 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berger, MS; Haas-Kogan, DA; Hirose, Y; Katayama, M; Pieper, RO; Stokoe, D | 1 |
1 other study(ies) available for temozolomide and sb 202190
Article | Year |
---|---|
The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Base Sequence; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; G2 Phase; Humans; Imidazoles; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pyridines; Temozolomide | 2003 |